Non Animal Testing Database

Synergistic therapy for breast cancer with miRNA and lipid nanoparticles

December 2016
Zhejiang University, Hangzhou, China
Cancer stem cells are a major obstacle in the treatment of breast cancer due to, among other things, their drug resistance capabilities. However, microRNA-200c has been described to reduce the expression of class III beta-tubulin, which recovers sensitivity to microtubule-targeting drugs. Here, a combination of microRNA-200c and paclitaxel mediated by lipid nanoparticles is used to target breast cancer stem cells in mammospheres generated with human breast cancer cells. The results show that the lipid nanoparticles protected microRNA-200c from degradation and had higher cellular uptake efficiency than other methods. Furthermore, the microRNA-200c could be efficiently released from the lipid complex inside the cell. Finally, the transfection of the microRNA-200c-lipid complex into breast cancer stem cells induced downregulation of class III beta-tubulin and enhanced paclitaxel-mediated cytotoxicity of breast cancer stem cells. Overall, the researchers develop a new drug release strategy to deliver microRNA-200c in target-specific areas that, when combined with chemotherapy, can induce cell death of breast cancer stem cells.
MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell
Fuqiang Hu
Added on: 10-30-2021
Back to Top
English German

Warning: Internet Explorer

The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.

Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!